Varicella zoster virus (VZV) pneumonia is associated with significant mortality, especially in the immunocompromised host. VZV-specific immunoglobulins (VZIG) are currently used as post-exposure prophylaxis for at-risk patients, but not as adjunctive therapy. A novel case of VZV pneumonia in an immunocompromised patient, treated successfully with intravenous VZIG in combination with acyclovir, is reported here.
Adjuvant treatment of severe varicella pneumonia with intravenous varicella zoster virus-specific immunoglobulins / D. Mangioni, G. Grasselli, C. Abbruzzese, A. Muscatello, A. Gori, A. Bandera. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 85(2019 Aug), pp. 70-73. [10.1016/j.ijid.2019.05.022]
Adjuvant treatment of severe varicella pneumonia with intravenous varicella zoster virus-specific immunoglobulins
D. Mangioni
Primo
;G. GrasselliSecondo
;A. GoriPenultimo
;A. BanderaUltimo
2019
Abstract
Varicella zoster virus (VZV) pneumonia is associated with significant mortality, especially in the immunocompromised host. VZV-specific immunoglobulins (VZIG) are currently used as post-exposure prophylaxis for at-risk patients, but not as adjunctive therapy. A novel case of VZV pneumonia in an immunocompromised patient, treated successfully with intravenous VZIG in combination with acyclovir, is reported here.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Mangioni_intJinfdis_1-s2.0-S1201971219302292-main.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.48 MB
Formato
Adobe PDF
|
1.48 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
